DBV Technologies S.A. (DBV.PA)

2.686 €

-0.10 (-3.66%)
Rating:
Recommendation:
-
Symbol DBV.PA
Price 2.686 €
Beta 1.334
Volume Avg. 0.11M
Market Cap 252.184M
Shares () -
52 Week Range 2.174-5.48
1y Target Est -
DCF Unlevered DBV.PA DCF ->
DCF Levered DBV.PA LDCF ->
ROE -44.34% Strong Sell
ROA -28.50% Sell
Operating Margin -
Debt / Equity 17.01% Neutral
P/E -1.81 Sell
P/B 1.19 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Daniel Tasse
Healthcare
Biotechnology
Paris

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.